Loading
Connective Tissue Disorders Research / Protease and Inhibitor Mechanisms · Journal article
Accounts of Chemical Research · September 2, 2026
Raises a question worth testing. It does not answer one.
This is a research account describing the rational design and mechanistic characterization of layer-by-layer elastin-like polypeptide nucleic acid nanoparticles (LENN), a modular nonviral gene delivery platform. In vitro studies demonstrate cellular uptake, endosomal escape, and gene silencing in bladder cancer cells, and an initial in vivo proof-of-concept shows tumor association following intravesical administration. The work is exploratory and does not yet establish therapeutic efficacy or clinical relevance.
Journal article. EGFR-positive bladder cancer cells in culture and orthotopic bladder cancer models in vivo.. Intervention: Layer-by-layer elastin-like polypeptide nucleic acid nanoparticles (LENN), with or without EGF targeting modification, carrying mRNA or siRNA..
Targeted LENN undergoes rapid internalization and endosomal escape in EGFR+ bladder cancer cells, enabling efficient mRNA expression and siRNA knockdown. EGF-modified LENN exhibited tumor association following intravesical administration in orthotopic bladder cancer models. LENN assembly uses electrostatic condensation with cyclodextrin-polyarginine conjugates and ELP shells via reversible host–guest interactions, producing nanoparticles capable of high RNA encapsulation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This platform is at an early exploratory stage and does not yet support clinical translation. Further work is needed to establish in vivo therapeutic efficacy, safety, manufacturability, and comparative advantage over existing nonviral and viral vectors before clinical consideration.
This is a mechanistic and design account of a novel nonviral delivery platform with in vitro proof-of-concept and preliminary in vivo tumor association data, lacking efficacy endpoints or clinical translation.
As stated by the source record.
This platform is at an early exploratory stage and does not yet support clinical translation. Further work is needed to establish in vivo therapeutic efficacy, safety, manufacturability, and comparative advantage over existing nonviral and viral vectors before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Conspectus Gene therapy has evolved into a cornerstone modality in modern medicine, with applications spanning antisense oligonucleotide treatments, RNA interference therapies, mRNA vaccines, in vivo CAR-T cell therapies, and CRISPR-mediated in vivo gene editing. The demands of this proliferating therapeutic approach compel the development of delivery systems that excel in achieving target specificity, repeat dosing compatibility, storage stability, and scalable manufacturability. Although viral vectors and lipid nanoparticles (LNPs) have achieved clinical success, they face inherent challenges in fully meeting these evolving requirements, highlighting the need for alternatives. Nonviral gene delivery is a highly complex process that requires the delivery system to strike the proper balance between plasma and shelf stability, appropriate kinetic response for cargo release in the target biological milieu, and capacity for resorption or clearance from the body to minimize acute and/or long-term toxicity. Elastin-like polypeptides (ELPs), derived from human tropoelastin motifs, have emerged as promising scaffolds due to their tunable properties, low immunogenicity, and biodegradable nature. A growing number of laboratories are embracing the potential of ELPs to advance novel gene delivery systems toward these goals. This Account describes our laboratory’s sustained contributions in the ELP field over the past decade, culminating in the layer-by-layer elastin-like polypeptide nucleic acid nanoparticle (LENN) platform, which is a modular and biomanufacturable nonviral gene delivery system. We pioneered a fast organic solvent extraction-precipitation purification for ELPs that is sequence independent, yields material with low endotoxin levels, and preserves the functionality of fusion domains. LENN assembly is achieved by the electrostatic condensation of nucleic acids using cyclodextrin-polyarginine conjugates to form the core, followed by coating with ELP shells through reversible host–guest interactions, producing nanoparticles capable of high RNA encapsulation. This Account presents a head-to-head design comparison of LENN versus LNPs, representative peptide-based vectors, and polymeric nonviral systems, illustrating the modularity of LENN that allows for independent optimization of key functional elements. Targeted LENN undergoes rapid internalization and endosomal escape in EGFR+ bladder cancer cells, enabling efficient mRNA expression and siRNA knockdown. Mechanistic studies confirm cellular entry via the clathrin-mediated uptake pathway and activation of lipid remodeling processes that facilitate cargo release. In an initial proof-of-concept study, EGF-modified LENN exhibited tumor association following intravesical administration in orthotopic bladder cancer models. These studies illustrate the modularity of the LENN design and its potential as a tunable, biocompatible platform for nucleic acid therapeutics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.